Where does IP Liberty Vision Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), IP Liberty Vision Corporation ranks #17,795 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does IP Liberty Vision Corporation hold?

IP Liberty Vision Corporation holds 16 US utility patents granted between 2015 and 2025, spanning 10 technology areas.

What is IP Liberty Vision Corporation's Innovation Score?

IP Liberty Vision Corporation has an Innovation Score of 35.0 out of 100 (top 50% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does IP Liberty Vision Corporation focus on?

IP Liberty Vision Corporation's top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 14 patents, ranking #259 of 1,943 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is IP Liberty Vision Corporation's patent grant rate increasing or decreasing?

IP Liberty Vision Corporation's recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for IP Liberty Vision Corporation's patents?

IP Liberty Vision Corporation's patents average 17.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the IP Liberty Vision Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

IP Liberty Vision Corporation

USPTO PatentsView assignee record - 16 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, IP ranks #17,795 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 10 technology areas.

#17,795
of 49,997 US assignees by volume: Top 50%
by Innovation Score (35.0/100): 17.9
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17795 · US Corporation #17,795 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,795/49,997
PHOTO-FINISH Ideal Warehouse…
CPC-FOCUS A61N · 10 areas
INNOV-THIN 35.0/100
CLAIMS-RICH 17.9 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ideal Warehouse Innovations Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How IP’s 35.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (28%) Velocity 3.3 pts (9%) Breadth 11.2 pts (32%) Claim depth 10.7 pts (31%)

Qualcomm Incorporated · highest

85
IP Liberty Vision · this assignee

35
3D Lighting… · lowest

7

What this shows IP's Innovation Score is 35.0/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for IP?

Each dot is one of IP’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). IP’s own 17.9 claims/patent is ABOVE the 14.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

IP vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where IP's grants concentrate

IP Liberty Vision Corporation is a focused PatentsView assignee: 10 CPC subclasses with 87.5% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2015. By volume, IP sits between Insectergy LLC and Inceptus Medical, LLC.

IP's three-year grant acceleration

IP Liberty Vision Corporation shows 3 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Insectergy

16
Institut Regional…

16
Intermetallics

16
Intrinsic ID B V

16
Ideal Warehouse I…

16
Hexima

16
Inception Institu…

16
Inceptus Medical

16
IP Liberty Vision ◀

16

What this shows IP holds 16 patents at rank #17,778, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near IP

By rank, the assignees closest to #17,778 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in IP's primary technology class.

IP's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

IP Liberty Vision Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	6.3%
2017	1	6.3%
2018	1	6.3%
2019	3	18.8%
2021	3	18.8%
2022	1	6.3%
2024	2	12.5%
2025partial year	4	25.0%

Which technologies does IP Liberty Vision Corporation patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 14

A61B - DIAGNOSIS; SURGERY; Identification 8

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 3

C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients 3

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 3

Y10T - Technical Subjects Covered BY Former US Classification 3

G21F - Protection Against X-radiation, Gamma Radiation, Corpuscular Radiation OR Particle BOMBARDMENT; Treating Radioactively Contaminated MATERIAL; Decontamination Arrangements Therefor 2

G21G - Conversion OF Chemical ELEMENTS; Radioactive Sources 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

IP Liberty Vision Corporation's patent record in context - here's where to go next.

IP Liberty Vision Corporation's lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 87.5% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #17,795 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare IP Liberty Vision Corporation against Insectergy LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.